Vaneck Biotech ETF BBH

$167.01 +1.57 (0.95%)

Valuation

Market cap
—
Revenue TTM
—
Net income TTM
—
P/E (trailing)
—
P/E (forward)
—
Profit margin
—
Debt to equity
—

Trading

Volume
16,066
Avg volume
—
Day's range
$166.24 – $167.22
Shares out
—
Stochastic %K
—
Beta
—
Analysts
—
Price target
—

Price

Company profile

The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Phone
888-658-8287

Stocktwits

Doozio Nov 12, 3:37 PM
$BBH $SMH $XBI the 😇 doesn’t protect YO. If XBI breaks down odds of this becoming a bear market and not an intermediate correction increase greatly. Bahhht these are Thursday 🐑 🎁s on da DLO
0 replies
Doozio Oct 29, 1:57 PM
As long as $XBI $BBH don’t bahhhreak down let $SMH carve out the bahhhtom of this large consolidation. Chop chop huckleberries……. 🧠👀
1 replies
Doozio Oct 21, 6:03 PM
$BBH 🧠👀
0 replies
AlphaBull_10M Sep 29, 4:53 PM
$QURE Down -38% but up more than 210% from premarket bottom if you were lucky to catch that. $LABU $LABD $BBH $IBB
0 replies
ZacksResearch Sep 25, 2:12 PM
🧬 Oncology is attracting billions in biotech funding as precision cancer therapies drive innovation. 💊 $FBT +29.8%, $BBH +23.8% & $BBP +29.9% YTD, offering diversified biotech exposure. 🔬 Explore biotech ETFs gaining from the oncology growth opportunity here 👇 https://www.zacks.com/stock/news/2993134/biotech-etfs-to-buy-as-cancer-drug-breakthroughs-accelerate?_gl=1%2Afsgjvj%2A_up%2AMQ..%2A_ga%2AMTE1Njc3ODQ5My4xNzkwMzIxOTEx%2A_ga_MXXMZ1PBF7%2AczE3OTAzMzQxNzAkbzQkZzAkdDE3OTAzMzQxNzAkajYwJGwwJGgxNDM0MDQ4NTcy&cid=sm-stocktwits-0-2993134-oc-39717&ADID=SYND_STOCKTWITS_TWEET_0_2993134_OC_39717
0 replies
MacroHard26 Jun 1, 5:40 PM
$RVMD $XBI $BBH $SPY $LABU Charles Zhu Reiterates Buy on RVMD, Maintains $263 Price Target on Strong Darax. Data and Regulatory Progress Revolution Medicines Is Maintained at Outperform by Oppenheimer $RVMD Wedbush reiterates Outperform on Revolution Medicines after ASCO data Revolution Medicines price target raised to $195 from $169 at H.C. Wainwright Wells Fargo Sticks to Its Buy Rating for Revolution Medicines (RVMD) Ami Fadia Reiterates Buy on Strong Daraxonrasib Data, Maintains $183 Price Target
0 replies
MacroHard26 Jun 1, 1:35 PM
$RVMD $SPY $IBB $XBI $BBH $RVMD - Revolutionary https://finance.yahoo.com/sectors/healthcare/articles/revolution-medicines-pancreatic-cancer-pill-024312342.html
0 replies
StocktwitsNews May 22, 7:08 PM
GILD Stock Jumps After Winning Accelerated FDA Approval For HDV Treatment $GILD $BBH $IBB https://stocktwits.com/news/equity/markets/gild-stock-jumps-after-winning-accelerated-fda-approval-for-hdv-treatment/cZgRlDmReYE
0 replies